Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OK-TRANSPLANT 2
NCT06396416Phase 4Recruiting
- Sponsor
- Western University
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of semaglutide in obesity (2 arms), sponsored by Western University. Primary endpoint: Feasibility of Recruitment at 12 months. Started Sep 2024; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06396416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06396416.